Form 8-K - Current report:
SEC Accession No. 0001213900-15-000762
Filing Date
2015-02-06
Accepted
2015-02-06 13:22:57
Documents
7
Period of Report
2015-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k020615_actiniumpharma.htm 8-K 34597
2 UNDERWRITING AGREEMENT f8k020615ex1i_actinium.htm EX-1.1 205289
3 FORM OF WARRANT ISSUED TO THE INVESTORS f8k020615ex4i_actinium.htm EX-4.1 82283
4 OPINION OF HISCOCK & BARCLAY, LLP. f8k020615ex5i_actinium.htm EX-5.1 8722
5 PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED FEBRUARY 6, 2015. f8k020615ex99i_actinium.htm EX-99.1 11154
6 GRAPHIC image_002.gif GRAPHIC 2725
7 GRAPHIC image_001.gif GRAPHIC 2747
  Complete submission text file 0001213900-15-000762.txt   351105
Mailing Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 15583505
SIC: 2834 Pharmaceutical Preparations